This project will be conducted under the leadership Professor Yohei Iguchi, Lecturer and Group Leader at Nagoya University. As part of this project, Jiksak will contribute its proprietary Neuron DDS platform to support the development of targeted therapeutic approaches. Jiksak remains committed to advance innovative solutions for intractable diseases and accelerate the translation of innovative therapeutic approaches through collaborations with leading academic institutions.

The post Announcing the “Program for research on Intractable diseased” has been selected by AMED. first appeared on Jiksak Bioengineering.

The post Closes 800M JPY Series B funding first appeared on Jiksak Bioengineering.

Mitsui Chemicals’s announcement link

https://jp.mitsuichemicals.com/en/release/2022/2022_0708.htm

The post Mitsui Chemicals, Jiksak Pursue Joint Development in Aim of Commercializing Nerve Tissue Generated From Human iPS Cells first appeared on Jiksak Bioengineering.

Using Jiksak’s Nerve Organoid chips, the researchers generated organoids from ALS patient-derived iPS cells, then harvested the acellular axons. RNA sequencing of the axons identified PHOX2B as a gene possibly involved in the pathogenesis of ALS.

The research paper titled “Reduced PHOX2B stability causes axonal growth impairment in motor neurons with TARDBP mutation” has been published in Stem Cell Reports with the full article available at: https://doi.org/10.1016/j.stemcr.2021.04.021

The same group of researchers published data identifying the Fos-B gene to be a key regulator of the FUS mutant ALS. These 2 works taken together highlight the usefulness of Jiksak’s technology in uncovering the pathology of axonal disorders.

About Jiksak

Jiksak Bioengineering, Inc. is a biotechnology company based in Kawasaki, Japan, which focuses on finding a cure for neurodegenerative and neuromuscular diseases, especially amyotrophic lateral sclerosis (ALS). Founded in 2017, the company has developed both synapse induction technology and a unique iPS cell-derived neural tissue analysis organoid. Jiksak’s platform provides an efficient method to actively drive drug discovery and toxicity testing.

For more information, please visit www.jiksak.co.jp/

Contact

info@jiksak.co.jp

The post Jiksak’s Nerve Organoids™ Used to Discover New Modulatory Gene for ALS Pathogenesis first appeared on Jiksak Bioengineering.

This device combines Jiksak’s unique Nerve Organoid with SDTC’s sensitive electrode chip, enabling non-invasive quantitative measurement of neuron firing. The novel technology is expected to speed up drug discovery and help elucidate neural disease pathology. Jiksak aims to begin sales of the device as soon as possible.

About Jiksak

Jiksak Bioengineering, Inc. is a biotechnology company based in Kawasaki, Japan, which focuses on finding a cure for neurodegenerative and neuromuscular diseases, especially amyotrophic lateral sclerosis (ALS). Founded in 2017, the company has developed both synapse induction technology and a unique iPS cell-derived neural tissue analysis organoid. Jiksak’s platform provides an efficient method to actively drive drug discovery and toxicity testing.

For more information, please visit www.jiksak.co.jp/

Contact

info@jiksak.co.jp

The post Jiksak and Sharp Display Technology Announce Jointly Developed Electrode Chip-embedded Nerve Organoid Device first appeared on Jiksak Bioengineering.

KAWASAKI, Japan – March 23, 2021 – Jiksak Bioengineering, Inc. (Jiksak), a biotechnology company focused on finding a cure for amyotrophic lateral sclerosis (ALS), today announced the first closing of Series B investment led by Cyberdyne, Inc. and CEJ Fund, an investment fund managed by a Cyberdyne subsidiary. Jiksak plans to use this latest funding to accelerate and advance its projects, focusing on ALS drug discovery and regenerative medicine businesses.

In addition to the investment, Jiksak and Cyberdyne have entered into a business alliance in which they will combine Jiksak’s unique nerve organoid technology with Cyberdyne’s expertise in Cybernics Treatment using the wearable cyborg HAL. The partners plan to develop therapies for ALS and other neuromuscular diseases.

Jiksak owns a proprietary phenotyping technology for nerve organoids, neural tissues derived from human iPS cells. Using this core technology, Jiksak successfully launched its organoid business through joint research with major companies as well as sales of nerve organoid products. The company has also accumulated data necessary for ALS drug discovery through analysis of ALS patient iPS-derived nerve organoids, necessitating additional funding to advance to the next stage of drug discovery.

About Jiksak

Jiksak Bioengineering, Inc. is a biotechnology company based in Kawasaki, Japan, which focuses on finding a cure for neurodegenerative and neuromuscular diseases, especially amyotrophic lateral sclerosis (ALS). Founded in 2017, the company has developed both synapse induction technology and a unique iPS cell-derived neural tissue analysis organoid. Jiksak’s platform provides an efficient method to actively drive drug discovery and toxicity testing.

For more information, please visit www.jiksak.co.jp/

Contact

info@jiksak.co.jp

The post Jiksak Partners with Cyberdyne for ALS Drug Discovery and Regenerative Medicine first appeared on Jiksak Bioengineering.